The androgen receptor is the major driver of prostate cancer growth and survival. However, almost all patients relapse with castration-resistant disease (CRPC) when treated with anti-androgen therapy. Research from Dr. Cindy Miranti, professor of Cellular and Molecular Medicine and Co-Program Leader of the Cancer Biology Research Program, discovered why these traditional therapies have failed in clinical trials to overcome androgen hormone-dependent CRPC.
